Cargando…

Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?

PURPOSE: Mutations affecting the KRAS gene are an established negative predictor for anti-epidermal growth factor receptor (anti-EGFR) therapies in metastatic colorectal cancer (CRC). However, the role of KRAS mutation as a biomarker for anti-vascular endothelial growth factor (VEGF) remains controv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Seung Tae, Park, Kyong Hwa, Shin, Sang Won, Kim, Yeul Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918527/ https://www.ncbi.nlm.nih.gov/pubmed/24520223 http://dx.doi.org/10.4143/crt.2014.46.1.48

Ejemplares similares

Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy
por: Kim, Seung Tae, et al.
Publicado: (2013)

Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?
por: Kim, Seung Tae, et al.
Publicado: (2015)

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
por: Kim, Mi-Jung, et al.
Publicado: (2012)

The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer
por: Choi, Yoon Ji, et al.
Publicado: (2016)

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations
por: Moon, Jai-Hee, et al.
Publicado: (2019)

KRAS and BRAF mutational status in colon cancer from Albanian patients
por: Martinetti, Daniela, et al.
Publicado: (2014)

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
por: Ribeiro, Karen Bento, et al.
Publicado: (2013)

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
por: Radanova, Maria, et al.
Publicado: (2023)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

The impact of KRAS mutations on VEGF-A production and tumour vascular network
por: Figueras, Agnès, et al.
Publicado: (2013)

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Se Hyun, et al.
Publicado: (2016)

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
por: Mekenkamp, Leonie JM, et al.
Publicado: (2012)

Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer
por: Pershad, Yash, et al.
Publicado: (2017)

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report
por: Cafiero, Concetta, et al.
Publicado: (2020)

Chemotherapy in Patients Older than or Equal to 75 Years with Advanced Non-small Cell Lung Cancer
por: Kim, Seung Tae, et al.
Publicado: (2012)

Clinical features and KRAS mutation in colorectal cancer with bone metastasis
por: Park, Hyung Soon, et al.
Publicado: (2020)

Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer
por: Lucchetti, Donatella, et al.
Publicado: (2021)

Completion rate of physician orders for life-sustaining treatment for patients with metastatic or recurrent cancer: a preliminary, cross-sectional study
por: Kim, Ju Won, et al.
Publicado: (2019)

Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report
por: El agy, Fatima, et al.
Publicado: (2021)

KRAS mutations are negatively correlated with immunity in colon cancer
por: Fu, Xiaorui, et al.
Publicado: (2020)

Heterogeneity of KRAS Mutation Status in Rectal Cancer
por: Jo, Peter, et al.
Publicado: (2016)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
por: Gattenlöhner, S., et al.
Publicado: (2009)

KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients
por: GUTIÉRREZ, CRISTINA, et al.
Publicado: (2013)

Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment
por: Lee, Jung Hyun, et al.
Publicado: (2014)

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
por: PALIOGIANNIS, PANAGIOTIS, et al.
Publicado: (2014)

The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer
por: Eshraghi, Abbas, et al.
Publicado: (2020)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Discovery and Evaluation of Polymorphisms in the AKT2 and AKT3 Promoter Regions for Risk of Korean Lung Cancer
por: Sung, Jae Sook, et al.
Publicado: (2012)

The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report
por: Kim, Hye Sook, et al.
Publicado: (2014)

The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis
por: Frouws, Martine A., et al.
Publicado: (2017)

Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma
por: Vittal, Anusha, et al.
Publicado: (2017)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production
por: Kim, Aeyung, et al.
Publicado: (2014)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
por: Lin, Yu-Lin, et al.
Publicado: (2012)

KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia
por: Juárez, Miriam, et al.
Publicado: (2017)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
por: Amram, Marie-Laure, et al.
Publicado: (2017)

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
por: Ucar, Gokhan, et al.
Publicado: (2020)

MEK inhibition suppresses metastatic progression of KRAS‐mutated gastric cancer
por: Yamasaki, Juntaro, et al.
Publicado: (2022)

Colorectal Cancer Prognosis Is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study
por: Lee, Joon-Hyop, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2q7snat7et1bg8tkhc9fpssf81